NIT
ESPR

NumerixS Investment Technologies’s Esperion Therapeutics ESPR Stock Holding History

NumerixS Investment Technologies’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,400
Closed -$391K – 1075
2019
Q2 		$391K Buy
8,400
+1,400
+20% +$65.7K 0.11% 226
2019
Q1 		$280K Buy
+7,000
New +$314K 0.04% 555
2018
Q4 		– Sell
-3,900
Closed -$175K – 1164
2018
Q3 		$175K Buy
+3,900
New +$179K 0.03% 631

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NumerixS Investment Technologies's ESPR Position: Q3 2019 in Review

NumerixS Investment Technologies sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 8,400 shares — an estimated $391K sold.

NumerixS Investment Technologies first reported a position in ESPR in Q3 2018 and held it in 3 quarters. The position peaked at $391K in Q2 2019. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • NumerixS Investment Technologies reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • NumerixS Investment Technologies sold 8,400 Esperion Therapeutics shares in Q3 2019, an estimated $391K.
  • NumerixS Investment Technologies first reported a position in Esperion Therapeutics in Q3 2018 and held it in 3 quarters.
  • NumerixS Investment Technologies's Esperion Therapeutics position peaked at $391K in Q2 2019.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on NumerixS Investment Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.